CN116966308A - 治疗神经内分泌前列腺癌的试剂和用途 - Google Patents

治疗神经内分泌前列腺癌的试剂和用途 Download PDF

Info

Publication number
CN116966308A
CN116966308A CN202210431313.7A CN202210431313A CN116966308A CN 116966308 A CN116966308 A CN 116966308A CN 202210431313 A CN202210431313 A CN 202210431313A CN 116966308 A CN116966308 A CN 116966308A
Authority
CN
China
Prior art keywords
ser
kit
ala
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210431313.7A
Other languages
English (en)
Chinese (zh)
Inventor
高栋
李飞
韩铭
张晔晗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Excellence in Molecular Cell Science of CAS
Original Assignee
Center for Excellence in Molecular Cell Science of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Excellence in Molecular Cell Science of CAS filed Critical Center for Excellence in Molecular Cell Science of CAS
Priority to CN202210431313.7A priority Critical patent/CN116966308A/zh
Priority to PCT/CN2023/078916 priority patent/WO2023202223A1/fr
Publication of CN116966308A publication Critical patent/CN116966308A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210431313.7A 2022-04-22 2022-04-22 治疗神经内分泌前列腺癌的试剂和用途 Pending CN116966308A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210431313.7A CN116966308A (zh) 2022-04-22 2022-04-22 治疗神经内分泌前列腺癌的试剂和用途
PCT/CN2023/078916 WO2023202223A1 (fr) 2022-04-22 2023-03-01 Réactif pour le traitement du cancer de la prostate neuroendocrinien et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210431313.7A CN116966308A (zh) 2022-04-22 2022-04-22 治疗神经内分泌前列腺癌的试剂和用途

Publications (1)

Publication Number Publication Date
CN116966308A true CN116966308A (zh) 2023-10-31

Family

ID=88419113

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210431313.7A Pending CN116966308A (zh) 2022-04-22 2022-04-22 治疗神经内分泌前列腺癌的试剂和用途

Country Status (2)

Country Link
CN (1) CN116966308A (fr)
WO (1) WO2023202223A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012067899A2 (fr) * 2010-11-15 2012-05-24 Vanderbilt University Foxa1 en tant que marqueur pour le cancer invasif de la vessie
CN108403659A (zh) * 2018-03-01 2018-08-17 中国科学院过程工程研究所 一种硬乳液纳微球及其制备方法和应用
EP3999117A4 (fr) * 2019-07-12 2023-07-26 Duke University Systèmes de nanoparticules pour l'administration ciblée de crispr/cas13 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
WO2023202223A1 (fr) 2023-10-26

Similar Documents

Publication Publication Date Title
CN111979290B (zh) Spp1基因在制备增强卵巢癌患者对parp抑制剂敏感性的药物中的应用
US20230293512A1 (en) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
Taguchi et al. Fatty acid–binding protein 4 downregulation drives calcification in the development of kidney stone disease
Zhao et al. microRNA‐206 overexpression inhibits epithelial‐mesenchymal transition and glomerulosclerosis in rats with chronic kidney disease by inhibiting JAK/STAT signaling pathway
CN112961916B (zh) Akr1c3作为肝癌预后的生物学标志物及其应用
CN110244056B (zh) Znf521基因在制备肝癌治疗药物、诊断及预后评估试剂中的应用
Liu et al. Exosomal miR‐27 negatively regulates ROS production and promotes granulosa cells apoptosis by targeting SPRY2 in OHSS
CN112867495A (zh) 包含syt11抑制剂作为活性成分的胃癌治疗组合物
Radnaa et al. Stress signaler p38 mitogen-activated kinase activation: a cause for concern?
WO2011129427A1 (fr) Agent de diagnostic et agent thérapeutique pour les cancers
CN116966308A (zh) 治疗神经内分泌前列腺癌的试剂和用途
KR102331240B1 (ko) Sgk3 유전자를 이용한 뇌신경계 질환의 진단 및 치료
KR102074559B1 (ko) 위암의 항암제 내성 진단용 바이오마커 및 이의 용도
CN112143805A (zh) Rit1在肝细胞癌的诊断和治疗中的应用
KR101774465B1 (ko) 암 치료 표적 Ｓｉｒｔ２ 및 그를 사용하여 암 치료제를 스크리닝하는 방법
Sun et al. GRP/GRPR signaling pathway aggravates hyperuricemia-induced renal inflammation and fibrosis via ABCG2-dependent mechanisms
CN114908158B (zh) Cdk1在晚期胃肠间质瘤的诊断和治疗中的应用
US11938164B2 (en) Exosome-based cancer assays
CN114134225B (zh) 一种类风湿关节炎（ra）诊断的生物标志物及其应用
Cheng et al. New murine model of alcoholic hepatitis in obesity-induced metabolic-associated fatty liver disease
Adle-Biassette et al. Sarco/endoplasmic reticulum calcium ATPase 3 (SERCA3) expression in gastrointestinal stromal tumours
Zhou et al. LY294002 Inhibit Proliferation, Migration, and Invasion of Craniopharyngiomas via PI3K/Akt Signaling Pathway
Wu et al. A study of protective effects of Mus81 in preeclampsia
Li et al. Abnormal activation of the Wnt3a/β-catenin signaling pathway promotes the expression of TBX3 and the EMT pathway to mediate the occurrence of adenomyosis
CN114908162A (zh) Rrm2在晚期胃肠间质瘤的诊断和治疗中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination